Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer
Go back to Rigel Enters Exclusive Global Licensing Agreement for VEPPANU™ (vepdegestrant), an oral PROTAC, for the Treatment of 2L+ ER+/HER2-, ESR1m Advanced or Metastatic Breast Cancer| Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) | Delayed: 40.26 +1.54 (3.98%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $38.72 | 52 Week High | $4.38 | |||
| Open | $38.80 | 52 Week Low | $1.88 | |||
| Day High | $40.33 | P/E | N/A | |||
| Day Low | $38.80 | EPS | $-1.12 | |||
| Volume | 449,682 | |||||
